Search

Reports that the management of menorrhagia has changed and effective medical and surgical therapies are now being widely used. Heavy menstruation in women; Investigation of and referral by a general practitioner; Role of hormone therapy; Effect of contraception. INSETS: Questions to ask in history taking;Take-home points.

The article presents the questions and answers related to hormonal intrauterine device (IUD) be used to help manage heavy or irregular bleeding that often occurs during the transition to menopause, and ganglion cyst.

The article presents a case study of a 49-year-old woman who developed reversible cerebral vasoconstriction syndrome after receiving leuprorelin treatment for menorrhagia.

Reports that a microwave aerial could provide a safe, quick and inexpensive treatment for menorrhagia. Drawbacks of hysterectomy as standard treatment; Destruction of the endometrium while leaving the underlying wall of the uterus unscathed as key to technique; Description of the aerial.

Focuses on photodynamic therapy (PDT) as treatment for menorrhagia. Sensitization of abnormal tissue to light; Introduction of aminolevulinic acid (ALA) into the uterus.

The article offers information on several issues related to new health developments in Great Britain. It mentions that patients in dementia case-finding diethylstilbestrol (DES) of Department of Health experience anxiety while waiting for result. It states that health minister Anna Soubry wants an investigation on the claims of Diabetes UK with glucose testing strips ration of general practitioners (GPs). Furthermore, Merina is found to treat menorrhagia effectively than the usual treatment.

This article discusses heavy menstrual bleeding, which is also known as menorrhagia. The condition is associated with an 80-milliliters (ml) or more objective monthly blood loss and bleeding with excessive flow at regular cycle intervals. Despite its objective nature, presentations of menorrhagia can be subjective, and thus, necessitate a thorough diagnosis.

The article presents a case study of 24-year-old woman who developed hypotension and rash after being treated with tranexamic acid for menorrhagia.

The article discusses a study published in the August 30, 2013 issue of the "American Journal of Obstetrics and Gynecology" that examined the quality of life (QOL) and costs of levonorgestrel-releasing intrauterine system (LNG-IUS) or hysterectomy in treating menorrhagia.

The article describes a case of a large decidual cast in a 13-year-old girl induced by the treatment with ethinylestradiol/norgestimate for adolescent menorrhagia. It relates the symptoms experienced by the patient. A description of the decidual cast discharged by the patient is given. The treatment administered to the patient and its outcome are outlined.

The article describes the case of a 39-year-old woman who developed endometrioid adenocarcinoma, after she was fitted with a levonorgestrel-releasing intrauterine system (IUS) for menorrhagia. The patient who has polycystic ovary syndrome was also receiving medroxyprogesterone when she was fitted with the IUS. Time to reaction onset is also stated.

The article describes the case of a 39-year-old woman whose pancytopenia worsened, after an iron sucrose therapy for severe iron deficiency and pancytopenia following chronic menorrhagia. A bone marrow biopsy showed a hypercellular marrow, a normal number of erythroid cells but with left-shifted erythropoiesis, and a slightly decreased number of megakaryocytes.

The article examines the case of a girl with tuberous sclerosis complex who developed a kidney angiomyolipoma during treatment with oral contraceptives for menorrhagia. She started receiving oral medroxyprogesterone at age 13.5 years. She then switched to ethinylestradiol/levonorgestrel followed by ethinylestradiol/desogestrel. An exophytic lesion protruding outwards from the anterior surface of her left kidney was seen on hear yearly renal ultrasound at the age of 14.5 years.

Discusses research being done on the clinical outcome and costs associated with levonorgestrel-releasing intrauterine system (LNG-IUS) and hysterectomy for the treatment of menorrhagia. Reference to a study by R. Hurskainen et al, published in March 24-31, 2004 issue of the "Journal of the American Medical Association"; Comparison between the direct costs incurred by the LNG-IUS group and the hysterectomy group; Potential problem concerning the utilization of LNF-IUS.

Discusses endometrial ablation, a surgical procedure for the endometrium. Efficacy in the treatment of excessive or prolonged menstrual bleeding or menorrhagia; Types of endometrial ablation techniques; Advantage over hysterectomy.

Presents information on a feasibility study on the use of uterine balloon therapy (UBT) for menorrhagia in the community setting. Background on treatment using the Thermachoice balloon; Details on the study procedure and subject characteristics; Comparison of the rate of pain between UBT and hysteroscopy.

Recommends Mirena, an intrauterine device for controlling menorrhagia or heavy menstrual bleeding. Positive results for the testing of Mirena.

States that doctors in Bath, England have discovered a way to treat women who are not planning to get pregnant but have heavy periods. Treatment known as menorrhagia; Procedure of treatment.